Crispr Therapeutics AG (CRSP) has released an update.
CRISPR Therapeutics AG and Vertex Pharmaceuticals have made a significant leap in gene therapy by securing a conditional marketing authorization from the European Commission for their groundbreaking treatment, CASGEVY™. This therapy is a game-changer for patients 12 and older suffering from severe sickle cell disease and beta thalassemia who lack a matching stem cell donor. It addresses a crucial unmet medical need, offering hope where traditional treatments fall short, and is set to be re-evaluated annually as more clinical data emerges.
For further insights into CRSP stock, check out TipRanks’ Stock Analysis page.
